Homepage
Healthcare · Biotechnology · United States · Updated May 10, 8:16pm
$5.16
Price
$23.5M
Market Cap
2
Employees
1.05
Beta
Geordan G. Pursglove
CEO
Business Description
Lixte Biotechnology Holdings, Inc. operates as a drug discovery company that uses biomarker technology to identify enzyme targets related with serious common diseases and designs novel compounds to attack those targets. The company primarily focuses on inhibitors of protein phosphatases that are used alone and in combination with cytotoxic agents and/or x-ray and immune checkpoint blockers; and encompasses two major categories of compounds at various stages of pre-clinical and clinical development. It develops two series of pharmacologically active drugs, which include the LB-100 series that consists of novel structures for the treatment of cancers, and vascular and metabolic diseases; and LB-200 series to treat chronic hereditary diseases, such as Gaucher's disease, as well as cancer and neurodegenerative diseases. Lixte Biotechnology Holdings, Inc. has a clinical trial research agreement with the Moffitt Cancer Center and Research Institute Hospital Inc.; collaboration agreement for an investigator-initiated clinical trial with the Spanish Sarcoma Group, as well as Netherlands Cancer Institute and Oncode Institute. The company was founded in 2005 and is based in Pasadena, California.
Business History
Price Overview
Last updated: May 11, 2026 1:52pm (just now)$5.03
-0.13 (-2.52%)
Day Range
$5.01 – $5.34
52-Week Range
$0.64 – $6.26
50-Day MA
$3.22
200-Day MA
$3.90
Volume
87,395.24
Share Structure
Outstanding
4,549,805.00
Float
4,550,370.00
Free Float
100.0%
High free float
— 100.0% of shares trade freely, ~-0% held by insiders/institutions
Very liquid — most shares trade freely. Low insider ownership can mean less management alignment, but makes large position sizing straightforward.
Small absolute float (4.6M shares) — even with a decent free float %, volume can be thin. Check average daily volume before sizing a position.
Price History (1 Year)
Revenue & Net Income Trend
The directional story — useful even when net income is negative.
Revenue
The top line — total sales before any costs or taxes are subtracted. A measure of how much business the company is doing.
Net Income
The bottom line — profit left after subtracting all expenses, interest, and taxes from revenue. Reflects accounting profitability, but includes non-cash items like depreciation, so it isn't the same as cash earned.
Operating Cash Flow
The real cash generated by the day-to-day business — selling products, paying suppliers, collecting from customers. Calculated from net income by adding back non-cash items and adjusting for timing (unpaid bills, unsold inventory). When OCF consistently lags net income, the reported profit may not be converting to real money.
| Period | Revenue | Net Income | Net Margin | YoY/QoQ |
|---|
Key Metrics
API Direct from provider
CALC Derived from statements
P/E Ratio (Price per dollar of earnings)
CALCStock Price / EPS (Diluted)
-4.10
Stock Price: $5.16
EPS (Diluted): -1.26
EPS (Diluted): -1.26
P/B Ratio (Price vs net asset value)
APIStock Price / Book Value Per Share
19.69
Stock Price: $5.16
Total Equity: $9.66M
Shares: 48,407,310
Total Equity: $9.66M
Shares: 48,407,310
EV/EBITDA (Total value vs operating profit)
APIEnterprise Value / EBITDA
-3.45
Market Cap: $23.48M
Total Debt: $69,073
Cash: $5.11M
EBITDA: -$6.00M
Total Debt: $69,073
Cash: $5.11M
EBITDA: -$6.00M
Enterprise Value (Takeover price (cap + debt - cash))
APIMarket Cap + Total Debt - Cash
$185.8M
Market Cap: $23.48M
Total Debt: $69,073
Cash: $5.11M
Total Debt: $69,073
Cash: $5.11M
Gross Margin (Revenue left after direct costs)
APIGross Profit / Revenue
0.0%
Gross Profit: $0.00
Revenue: $0.00
Revenue: $0.00
Operating Margin (Revenue left after all operations)
APIOperating Income / Revenue
0.0%
Operating Income: -$5.11M
Revenue: $0.00
Revenue: $0.00
Net Margin (Revenue left as actual profit)
APINet Income / Revenue
0.0%
Net Income: -$6.01M
Revenue: $0.00
Revenue: $0.00
ROE (Profit from shareholder equity)
APINet Income / Total Equity
-147.9%
Net Income: -$6.01M
Total Equity: $9.66M
Total Equity: $9.66M
ROIC (Profit from all invested capital)
APINOPAT / Invested Capital
-42.3%
Operating Income: -$5.11M
Tax Rate: 0.0%
Equity: $9.66M
Total Debt: $69,073
Cash: $5.11M
Tax Rate: 0.0%
Equity: $9.66M
Total Debt: $69,073
Cash: $5.11M
Current Ratio (Can it pay short-term bills)
APICurrent Assets / Current Liabilities
3.88
Current Assets: $5.18M
Current Liabilities: $1.33M
Current Liabilities: $1.33M
Debt/Equity (Leverage — debt vs equity)
CALCTotal Debt / Total Equity
0.01
Short-Term Debt: $69,073
Long-Term Debt: $0.00
Total Debt: $69,073
Total Equity: $9.66M
Long-Term Debt: $0.00
Total Debt: $69,073
Total Equity: $9.66M
Rev/Share (Top-line per share)
Revenue / Shares Outstanding
—
Revenue: $0.00
Shares: 48,407,310
Shares: 48,407,310
Book Value/Share (Net assets per share)
CALC(Total Assets - Total Liabilities) / Shares
$0.20
Total Equity: $9.66M
Shares: 48,407,310
Shares: 48,407,310
FCF/Share (Real cash generated per share)
CALC(Operating Cash Flow + CapEx) / Shares
$-0.06
Operating CF: -$3.07M
CapEx: $0.00
Shares: 48,407,310
CapEx: $0.00
Shares: 48,407,310
Div Yield (Annual income from holding)
APILast Annual Dividend / Stock Price
0.0%
Last Dividend: N/A
Stock Price: $5.16
Stock Price: $5.16
Payout Ratio (Earnings paid out as dividends)
Dividends Paid / Net Income
—
Dividends Paid: N/A
Net Income: -$6.01M
Net Income: -$6.01M
Dividends paid not available in cash flow statement
Industry Benchmarks
Compares LIXT against LLM-researched typical ranges for its
industry. One research call per industry, cached indefinitely — every stock in the same industry
reuses the same baseline.
Deep Analysis
Pre-flight intelligence scans the company first, then routes to the right analytical methods.
0
Company Classification
— What type of company is this?
1
Industry Landscape
— Where is the industry headed?
2
Company Momentum
— Where is this company trending?
3
Forward Projection
— 1Y & 2Y projected metrics (requires Layer 1 + 2)
4a
DCF Valuation
— Present value of future cash flows
4b
Earnings Power Value
— Floor value — worth with zero growth
4c
Anchored PE
— Industry PE adjusted for growth differential
4d
Reverse DCF
— What growth is the market pricing in?
4e
Revenue-Based DCF
— For growth/narrative companies (skip if mature earner)
4f
Anchored P/S
— Price-to-Sales peer comparison (skip if mature earner)
4g
Scenario Analysis
— Bull / Base / Bear (skip if mature earner)
4h
Dividend Discount Model
— For dividend/income stocks only
4i
Book Value Analysis
— For deep value / turnaround stocks only
4j
Insider Activity
— Are insiders buying or selling?
4f
Cash Flow Quality
— How trustworthy is the FCF?
4g
Debt Maturity Risk
— Can it handle its debt?
4h
Macro Environment
— Rates, market valuation, volatility
4i
Sector Intelligence
— How does this company compare within its sector?
4j
Revenue Confidence
— How reliable is the growth projection?
4k
Sensitivity Analysis
— How fragile is the fair value estimate?
4l
Sector Demand Cycle
— Is the sector in a boom, steady state, or contraction?
5
AI Investigation
— Adaptive research engine (Claude)
5b
Thesis Evaluation
— What does the market believe? (narrative/platform stocks only)
6
Valuation Synthesis
— Weighted verdict from all methods (requires Layer 4)
Income Statement (Annual)
| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 |
| Cost of Revenue | $0 | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 | $0 | $0 |
| Operating Expenses | $6.7M | $6.3M | $5.1M | $3.6M | $5.1M |
| Operating Income | -$6.7M | -$6.3M | -$5.1M | -$3.6M | -$5.1M |
| Net Income | -$6.7M | -$6.3M | -$5.1M | -$3.6M | -$6.0M |
| EBITDA | -$6.7M | -$6.3M | -$5.1M | -$3.6M | -$6.0M |
| EPS | $-5.00 | $-4.00 | $-2.66 | $-1.59 | $-1.26 |
| EPS (Diluted) | — | — | — | — | — |
Balance Sheet (Annual)
| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | $4.8M | $5.4M | $4.2M | $1.0M | $5.1M |
| Total Current Assets | $5.1M | $5.6M | $4.3M | $1.0M | $5.2M |
| Total Assets | $5.1M | $5.6M | $4.3M | $1.1M | $12.7M |
| Current Liabilities | $302,926 | $395,756 | $313,858 | $318,284 | $1.3M |
| Long-Term Debt | $0 | $0 | $0 | $0 | $0 |
| Total Liabilities | $302,926 | $395,756 | $313,858 | $318,284 | $1.8M |
| Total Equity | $4.8M | $5.2M | $4.0M | $827,219 | $9.7M |
| Retained Earnings | -$37.1M | -$43.4M | -$48.5M | -$52.1M | -$58.1M |
Cash Flow (Annual)
| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Operating Cash Flow | -$4.1M | -$4.6M | -$4.3M | -$3.2M | -$3.1M |
| Capital Expenditure | $0 | $-3 | $0 | $-4 | $0 |
| Free Cash Flow | -$4.1M | -$4.6M | -$4.3M | -$3.2M | -$3.1M |
| Acquisitions (net) | $0 | $0 | $0 | $0 | $0 |
| Debt Repayment | — | — | — | — | — |
| Dividends Paid | — | — | — | — | — |
| Stock Buybacks | $0 | $0 | $0 | $0 | $0 |
| Net Change in Cash | $-245,521 | $529,647 | -$1.1M | -$3.2M | $4.1M |
Growth Trends (YoY %)
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Revenue Growth | — | — | — | — |
| Gross Profit Growth | — | — | — | — |
| Operating Income Growth | +6.1% | +19.3% | +29.8% | -43.0% |
| Net Income Growth | +6.2% | +19.4% | +29.5% | -67.6% |
| EBITDA Growth | +6.2% | +19.6% | +29.6% | -68.1% |
Insider Trading (Recent)
| Date | Insider | Type | Shares | Price | Value |
|---|---|---|---|---|---|
| 2026-04-15 | Pursglove Geordan Garrett | A-Award | 350,000.00 | $0.00 | $0 |
| 2026-04-15 | Pursglove Geordan Garrett | D-Return | 350,000.00 | $2.83 | $990,500 |
| 2026-04-15 | Stazzone Peter | A-Award | 50,000.00 | $0.00 | $0 |
| 2026-04-15 | Stazzone Peter | D-Return | 50,000.00 | $4.45 | $222,500 |
| 2026-04-15 | Sawyer Jason David | A-Award | 25,000.00 | $0.00 | $0 |
| 2026-04-15 | Felix Lourdes | A-Award | 25,000.00 | $0.00 | $0 |
| 2026-04-15 | Felix Lourdes | D-Return | 25,000.00 | $4.05 | $101,250 |
| 2026-04-15 | Sawyer Jason David | D-Return | 25,000.00 | $3.59 | $89,750 |
| 2026-04-15 | Primus Guy Warren | A-Award | 25,000.00 | $0.00 | $0 |
| 2026-04-15 | Holloway Michael Andrew | A-Award | 25,000.00 | $0.00 | $0 |
| 2026-04-15 | Holloway Michael Andrew | D-Return | 25,000.00 | $3.59 | $89,750 |
| 2026-04-15 | Primus Guy Warren | D-Return | 25,000.00 | $4.05 | $101,250 |
| 2025-12-24 | Primus Guy Warren | A-Award | 25,000.00 | $4.05 | $101,250 |
| 2025-12-24 | Felix Lourdes | A-Award | 25,000.00 | $4.05 | $101,250 |
| 2025-09-01 | Primus Guy Warren | 0.00 | $0.00 | $0 | |
| 2025-09-01 | Stazzone Peter | A-Award | 50,000.00 | $4.45 | $222,500 |
| 2025-09-01 | Stazzone Peter | 0.00 | $0.00 | $0 | |
| 2025-09-01 | Felix Lourdes | 0.00 | $0.00 | $0 | |
| 2025-08-15 | Sawyer Jason David | A-Award | 25,000.00 | $3.59 | $89,750 |
| 2025-08-15 | Holloway Michael Andrew | A-Award | 25,000.00 | $3.59 | $89,750 |
No community reviews yet for LIXT.
Be the first — export the analysis to your AI and contribute back.
My Notes
personal — only you see this
Sign in to save personal notes and rate your interest in this stock.
Data via Financial Modeling Prep · Cached for performance · fmp
v1.1.193 · 1946f027 · 2026-05-08 18:57:27